National Comprehensive Cancer Network

About NCCN

NCCN Guidelines™ and NCCN Compendium™ Updated

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) and NCCN Drugs & Biologics Compendium (NCCN Compendium™) for Prostate Cancer.  These NCCN Guidelines™ are currently available as Version 2.2010.

The NCCN Prostate Panel added sipuleucel-T as a category 1 treatment recommendation for patients with castration-recurrent prostate cancer.  Sipuleucel-T is appropriate for asymptomatic or minimally symptomatic patients with ECOG performance status 0-1. It is not recommended for patients with visceral disease and a life expectancy less than 6 months.

For the complete updated versions of the NCCN Guidelines™ and the NCCN Compendium™ please visit NCCN.org.